Kiniksa Launches DTC Campaign to Reach 40,000 Recurrent Pericarditis Patients
Kiniksa has launched Heart’s Home, a Direct-to-Consumer campaign for ARCALYST across connected TV, digital and social media to educate roughly 40,000 U.S. patients with recurrent pericarditis on treatment options. ARCALYST is the first FDA-approved IL-1 blocker for recurrent pericarditis, offering weekly subcutaneous dosing to prevent flare-ups.
1. Campaign Launch
Kiniksa has introduced Heart’s Home, a multi-channel Direct-to-Consumer campaign for ARCALYST, deploying connected TV ads, digital placements and social media to identify, educate and empower patients living with recurrent pericarditis to discuss treatment options with their healthcare providers.
2. Patient Market Opportunity
Recurrent pericarditis affects approximately 40,000 U.S. patients annually, with an estimated 14,000 experiencing two or more flares due to persistent disease or inadequate response to NSAIDs, colchicine and steroids, highlighting a significant underserved patient population.
3. ARCALYST Profile and Strategy
ARCALYST, a weekly subcutaneous recombinant fusion protein that blocks IL-1α and IL-1β, is the first and only FDA-approved therapy for reducing recurrence risk in adults and children 12 and older, supported by Kiniksa’s expanding commercial infrastructure and targeted educational initiatives.